| Literature DB >> 32350931 |
Mirko Filippetti1,2, Lucia Cazzoletti3, Francesco Zamboni1, Pietro Ferrari1, Cristian Caimmi4, Nicola Smania2, Stefano Tardivo3, Marcello Ferrari1.
Abstract
OBJECTIVE: The aim was to evaluate the effect of a home-based exercise program on functional capacity, health-related quality of life (HRQoL), and disability, in patients with systemic sclerosis (SSc).Entities:
Keywords: disability; exercise therapy; muscles; quality of life; resistance training; scleroderma
Mesh:
Year: 2020 PMID: 32350931 PMCID: PMC7496851 DOI: 10.1111/sms.13702
Source DB: PubMed Journal: Scand J Med Sci Sports ISSN: 0905-7188 Impact factor: 4.221
Figure 1Flow diagram
Baseline characteristics of the randomized patients
| Control group (n = 22) | Intervention group (n = 22) | |
|---|---|---|
| Age (years) | 61.80 ± 14.40 | 63.60 ± 10.40 |
| Female sex (%) | 79.20 | 80.00 |
| BMI (kg/m2) | 24.70 (23.50;28.20) | 26.20 (24.00;28.30) |
| lcSSC (%) | 75.00 | 56.00 |
| Disease duration (years) | 11.50 (7.00;17.50) | 10.00 (6.00;16.00) |
| Modified Rodnan skin score | 6.50 ± 3.90 | 8.60 ± 5.50 |
| FEV1% predicted | 99.0 (91.50;104.50) | 90.00 (81.00;90.00) |
| VC % predicted | 110.50 (98.00;115.00) | 101.00 (87.00;113.00) |
| DLCO % predicted | 73.80 ± 17.90 | 64.20 ± 21.40 |
| PAPs (mm Hg) | 29.50 (22.00;30.50) | 28.00 (23.00;31.00) |
| Current treatment | ||
| Iloprost (%) | 91.70 | 96.00 |
| Calcium channel blockers (%) | 25.00 | 32.00 |
| Corticosteroids (%) | 16.70 | 12.00 |
| Mycofenolate mofetil (%) | 12.50 | 12.00 |
| Azathioprine (%) | 4.00 | 8.00 |
|
| 0.00 | 4.00 |
| Hydroxychloroquine (%) | 16.70 | 24.00 |
Measures are expressed as mean ± SD or median (Q1;Q3) using parametric and no parametric tests, respectively, or as percentages where appropriate.
Abbreviations: BMI, body mass index; DLCO, diffusion lung CO; FEV1, forced expiratory volume; lcSSC, limited cutaneous systemic sclerosis; PAPs, pulmonary artery pressure systolic; VC, vital capacity.
P ≤ .05.
Outcome measures
| Baseline | 3 months | 6 months |
| |
|---|---|---|---|---|
| 6MWD (m) | ||||
| IG | 486 (458;513) | 518 (492;544) | 532 (504;561) | <.0001 |
| CG | 464 (431;497) | 461 (432;489) | 459 (427;490) | |
| VO2peak (mlO2/kg/min) | ||||
| IG | 18.17 (15.64;20.70) | 20.27 (17.84;22.70) | 20.91 (18.46;23.35) | .8531 |
| CG | 16.07 (13.38;18.77) | 17.56 (14.72;20.40) | 18.13 (15.42;20.84) | |
| Weight (kg) | ||||
| IG | 71.00 (65.00;76.80) | 70.20 (64.40;76.00) | 69.80 (64.20;75.40) | .0001 |
| CG | 65.90 (60.80;71.00) | 66.00 (61.00;71.20) | 66.30 (61.10;71.40) | |
| Free fat mass (kg) | ||||
| IG | 47.80 (44.70;51.00) | 48.00 (44.90;51.20) | 48.10 (45.00;51.30) | .5938 |
| CG | 45.20 (42.30;48.20) | 45.30 (43.40;48.20) | 45.10 (42.20;48.00) | |
| Fat mass (kg) | ||||
| IG | 23.00 (18.90;27.30) | 22.20 (18.00;26.40) | 21.60 (17.60;25.70) | .0149 |
| CG | 20.70 (16.80;24.60) | 20.80 (16.90;24.60) | 20.80 (17.10;24.60) | |
| SF36‐PCS | ||||
| IG | 39.80 (36.30;43.20) | 45.30(42.30;48.30) | 46.70 (43.70;49.70) | <.0001 |
| CG | 45.10 (41.50;48.80) | 43.90 (40.10;47.80) | 43.20 (39.70;46.70) | |
| SF36‐MCS | ||||
| IG | 49.10 (46.00;52.30) | 51.60 (48.80;54.50) | 50.30 (46.90;53.70) | .1494 |
| CG | 45.10 (41.70;48.50) | 44.30 (41.20;47.30) | 43.60 (40.00;47.20) | |
| HAQ‐DI | ||||
| IG | 0.39 (0.23;0.55) | 0.26 (0.10;0.42) | 0.20 (0.06;0.35) | .0106 |
| CG | 0.29 (0.12;0.46) | 0.29 (0.12;0.47) | 0.30 (0.12;0.47) | |
| HAMIS (mean right hands) | ||||
| IG | 1.11 (0.20;2.02) | 0.89 (0.14;1.64) | 0.83 (0.10;1.56) | .3926 |
| CG | 0.97 (0.38;1.55) | 0.67 (0.12;1.22) | 0.77 (0.24;1.31) | |
| Handgrip (kg) | ||||
| IG | 24.60 (20.20;29.00) | 26.40 (21.90;30.80) | 27.30 (22.70;32.00) | .0030 |
| CG | 23.20 (19.30;27.00) | 22.90 (19.00;26.70) | 22.50 (18.30;26.60) | |
| Quadriceps strength (kg) | ||||
| IG | 22.30 (18.70;25.80) | 24.40 (20.70;28.10) | 26.00 (22.00;29.80) | .0001 |
| CG | 20.60 (17.20;24.10) | 20.00 (16.60;23.40) | 20.00 (16.80;23.30) | |
| Biceps strength (kg) | ||||
| IG | 11.30 (9.10;13.50) | 12.70 (10.50;14.80) | 13.60 (11.30;15.90) | <.0001 |
| CG | 11.80 (9.70;13.80) | 11.20 (9.40;13.00) | 11.00 (9.20;12.90) | |
Measures are expressed as mean predicted levels by regression models with 95% CI (see method section).
Abbreviations: 6MWT, 6 minutes walking test; CG: control group; IG: intervention group; HAMIS, hand mobility in scleroderma test; HAQ‐DI, health assessment questionnaire disability index; MCS, mental component score; PCS, physical component score; SF‐36, short‐form 36.
Average of both sides of maximum isometric contraction.
P per group interaction.
P ≤ .05.
Figure 2Temporal trend of performance outcome measures of patients in IG and CG. Legend: The error bars represent the 95% confidence interval of the outcome estimates. *P ≤ .05 of time per group interaction. ● Intervention group (IG); ○ control group (CG)
Figure 3Temporal trend in quality of life and disability outcome measures of patients in the IG and CG. Legend: SF‐36: short‐form 36; PCS: physical component score; MCS: mental component score; HAQ‐DI: health assessment questionnaire disability index. The error bars represent the 95% confidence interval of the outcome estimates. *P ≤ .05 of time per group interaction. ● Intervention group (IG); ○ control group (CG)